September is World Alzheimer’s Month. Today’s guest author, Marc Wortmann, the Executive Director at Alzheimer’s Disease International talks about the international campaign and the recommendations laid out by this year’s annual report.
World Alzheimer’s Month is the global awareness month for Alzheimer’s disease and other dementias. This is an important month to have because in large parts of the world dementia is still considered a normal part of ageing, rather than a disease of the brain. Alzheimer’s Disease International coordinates awareness and public policy efforts and uses this month to launch its World Alzheimer Report.
This year, the World Alzheimer Report 2014 focuses on modifiable risk factors. It shows there is strong evidence that cardiovascular risk factors, as well as …
Our guest author, Ali. A. Mokdad is based at University of Texas and affiliated with the Institute of Health Metrics and Evaluation (IMHE). He is the lead author of a recent study published in BMC Medicine, focusing on deaths caused by liver cirrhosis.
Liver cirrhosis is a costly disease that is devastating to families and their finances. Most of these deaths are preventable, however. Countries can reverse the tide of liver cirrhosis by implementing a variety of cost-effective solutions.
When my colleagues and I saw just how many deaths occurred each year as a result of liver cirrhosis, we decided to write a paper to raise awareness about these disease trends and the steps that could be taken …
While not all rare diseases are genetic, individual genetic disorders are rare. But despite individual genetic disorders being rare, collectively they affect 1 in 25 children. Furthermore, 80% of rare diseases are caused by faulty genes. Therefore when we discuss genetic diseases it is in essence a discussion on rare diseases.
Today marks Jeans for Genes Day, a fundraising event organized by Genetic Disorders UK to raise money for causes that help children with genetic diseases. There are more than 6,000 known genetic disorders, and this number is constantly increasing as patient sequencing technologies become more accessible. Genetic diseases can affect a person’s senses, movement, ability to learn or appearance, and can range from split-hand/split-foot malformation, a congenital …
Last year, a rainbow coalition of civil liberties campaigners, cancer patients and eminent geneticists – heck, even Jim Watson! – argued before the US Supreme Court that gene sequences are a product of nature and therefore ineligible for patent protection.
And the Supreme Court replied, in all its refined wisdom:
A nine-to-nothing unanimous decision.
A difference of opinion
But the US has long known that truths held to be 'self-evident' are not always in for a smooth ride, and so we perhaps should not be too surprised – if still perplexed and saddened – to learn that the Australian Federal Court, when faced with the same question, responded: 'um, maybe not'.
I do not pretend to understand what brand of logic could …
In this guest post, Dr Andrew Teschendorff of University College London and the CAS-MPG Partner Institute for Computational Biology, Shanghai, examines a new Genome Medicine study.
In an exciting research article published today in Genome Medicine, Rafa Irizzary and colleagues provide evidence for a gradual systems-level deregulation of the epigenome in stages prior to the onset of cancer and which later is seen to progress further in cancer. Thus, these insights could potentially lead to a clinical test with the ability to predict cancer risk in cells that are not yet malignant.
The authors focused on a specific epigenetic mark, known as DNA methylation, a molecular modification of DNA which can regulate the activity of nearby …
Breast cancer – the most common type of cancer affecting women – is often thought of as a single disease. However, mounting evidence suggests that there are multiple subtypes, all of which occur at different rates, have varying levels of aggressiveness, and respond to different types of treatment.
One of the better understood subtypes is HER2-positive breast cancer, defined by high expression of the HER2 protein. Women with HER2-positive breast cancer are often treated with targeted therapies such as trastuzumab, which has dramatically improved survival rates from HER2-positive breast cancer in the past decade.
Progress in treating HER2-positive breast cancer
In a Q&A podcast published in BMC Medicine to launch our Spotlight on breast cancer …
Reports over the rapid spread of the Ebola virus in West Africa are rife, and fears are growing that the virus could spread to other continents. We spoke to Greg Martin, Editor-in-Chief of Globalization and Health to get some answers about what Ebola is, how it presents, and what to do if you suspect a case. Dr Martin is Consultant to the World Health Organization.
What is your experience of Ebola?
I was working as a medical student in 1996 when a nurse, Marilyn Lahana, was treated for Ebola virus by the unit I was connected to. Marilyn had contracted the disease from a doctor who had flown into Johannesburg from Gabon for treatment. You can hear more about this …
The field of imaging and diagnostics is constantly advancing, with new technologies and innovations regularly being introduced. In this changing environment, how do clinicians ensure they keep up, and that their patients are receiving the right services? In this guest post, Rosa Sicari, co-Editor-in-Chief of Cardiovascular Ultrasound introduces a new ‘How I do it’ article series to help tackle these challenges.
Today echocardiography is one of the most widely used diagnostic tests in cardiology. Largely due to its cost-effectiveness, its high clinical yield, the ability to assess anatomy and function, contractility and coronary flow reserve, and heart valve status, all in the same sitting; and, most importantly, an ease of communication as it is performed by the cardiologists who translate …
Neglected Tropical Diseases (NTDs) are a group of 17 infectious diseases caused by pathogenic viruses, protozoa, helminths and bacteria. As a group, the socio-economic impact of NTDs on countries where they are endemic is comparable to malaria, AIDS or tuberculosis but, as you might guess from the term ‘neglected’, research into them doesn’t receive as much funding or attention.
We tend to consider NTDs as a problem for tropical areas of Asia, Africa and the Americas, but just because they are traditionally a burden to these regions, doesn’t mean that they can’t be a real issue for people from outside the tropics.
With climate change we are seeing (and will continue to see) the migration of parasite vectors from tropical regions to more …
It’s been a bumper month on the BioMed Central blogs, so we wouldn’t be surprised if you’ve missed a few posts. Not to worry though, as we’ve pulled together all the highlights right here.
The new Impact Factors are coming…
(Or rather, they’ve now arrived!) Now is the time of year when journal editors all over the world sit repeatedly clicking ‘refresh’ on their browsers. Up? Down? Staying the same? What will happen to their journal’s Impact Factor when the Journal Citation Report is published? Diana Marshall, Senior Managing Editor of the BMC series, wrote about how the new Impact Factors will affect her journals, and the publishing world as a whole.
Swimmer’s itch: sailors, fishermen and swimmers beware
For those in the …